UBS Group
RXRX icon

UBS Group’s Recursion Pharmaceuticals RXRX Stock Holding History

UBS Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$132K Hold
43,152
– – ﹤0.01% 6858
2025
Q4 		$176K Sell
43,152
-144,948
-77% -$718K ﹤0.01% 6644
2025
Q3 		$918K Buy
+188,100
New +$988K ﹤0.01% 5647

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group's RXRX Position: Q1 2026 in Review

UBS Group increased its Recursion Pharmaceuticals (RXRX) stake by 38% in Q1 2026, buying an estimated $5.45M and bringing the position to 5,101,237 shares worth $15.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2857.

UBS Group first reported a position in RXRX in Q2 2021 and has held it in 20 quarters since. The position peaked at $29.5M in Q1 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • UBS Group held 5,101,237 shares of Recursion Pharmaceuticals worth $15.7M as of Q1 2026.
  • UBS Group bought 1,409,215 Recursion Pharmaceuticals shares in Q1 2026, an estimated $5.45M.
  • Recursion Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #2857 holding.
  • UBS Group first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • UBS Group's Recursion Pharmaceuticals position peaked at $29.5M in Q1 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.